Patient-derived organoids for prediction of treatment response in oesophageal adenocarcinoma
Br J Surg
.
2024 Jan 3;111(1):znad408.
doi: 10.1093/bjs/znad408.
Authors
Jarlath C Bolger
1
2
,
Jonathan Allen
3
,
Nikolina Radulovich
4
,
Christine Ng
4
,
Mathieu Derouet
3
,
Premalatha Shathasivam
3
,
Gavin W Wilson
3
,
Ming-Sound Tsao
5
,
Elena Elimova
6
,
Gail E Darling
1
3
,
Jonathan C Yeung
1
3
Affiliations
1
Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
2
Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
3
Latner Thoracic Surgery Research Laboratories, Princess Margaret Cancer Research Tower, University Health Network, Toronto, Ontario, Canada.
4
Princess Margaret Living Biobank, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
5
Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada.
6
Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
PMID:
38284787
DOI:
10.1093/bjs/znad408
No abstract available
MeSH terms
Adenocarcinoma* / pathology
Adenocarcinoma* / therapy
Esophageal Neoplasms* / pathology
Esophageal Neoplasms* / therapy
Humans
Organoids / pathology
Supplementary concepts
Adenocarcinoma Of Esophagus
Grants and funding
RCSI
Cancer Research Society